Lunenfeld-Tanenbaum Research Institute, Toronto, Ontario, Canada
Dr. Pamela Goodwin has been actively involved in research relating to host factors in breast cancer for the past 25 years. Early in her career, she became intrigued with the possibility that host (patient-related) factors, especially obesity, might impact outcomes of women diagnosed with breast cancer. She began a program of research that has focused on the role of these factors, including obesity, nutrition, exercise and related factors in the clinical course of breast cancer. She has led a number of studies which investigate the complex interactions between body size, nutrition, exercise and physiologic mediators such as insulin, IGF-I and vitamin D, examining the impact of these factors on risk and survival of women diagnosed with breast cancer. Dr. Goodwin has expanded this work to investigate the status of long-term breast cancer survivors and the influences of hereditary factors, vitamin D and metformin on breast cancer outcomes. She currently leads a large international Phase III trial (NCIC MA.32) which examines the impact of an insulin lowering drug, metformin, on breast cancer outcomes and has an active translational research program examining the interface between host factors and tumor biology in both early and advanced breast cancer. She leads the Hold’Em for Life Translating Research Discoveries into Breast Cancer Cures Program at Mount Sinai Hospital and the Princess Margaret Cancer Centre.
Dr. Goodwin is a Professor of Medicine at the University of Toronto, with cross appointments in the Department of Health Policy, Management and Evaluation and in the School of Graduate Studies. She is a Senior Investigator at the Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Director of the hospital's Marvelle Koffler Breast Centre, holder of the Marvelle Koffler Chair in Breast Research and long-term grantee of the Breast Cancer Research Foundation. She has published over 200 articles in leading journals. She is also active in the clinical management of breast cancer patients.